| RRC ID |
52408
|
| Author |
Terada K, Matsushima Y, Matsunaga K, Takata J, Karube Y, Ishige A, Chiba K.
|
| Title |
The Kampo medicine Yokukansan (YKS) enhances nerve growth factor (NGF)-induced neurite outgrowth in PC12 cells.
|
| Journal |
Bosn J Basic Med Sci
|
| Abstract |
Accumulating evidence indicates that neurotrophic factor-like substances involved in the induction of neurotrophic factor synthesis may aid in the treatment of neurological disorders, such as Alzheimer's disease. Yokukansan (YKS), a traditional Kampo medicine, has been used for the treatment of anxiety and mood disorders. In the present study, we aimed to identify the signaling pathways associated with YKS-mediated enhancement of nerve growth factor (NGF)-induced neurite extension in rat pheochromocytoma (PC12) cells. Akt and extracellular-regulated kinase 1/2 (ERK1/2) phosphorylation levels were assessed by western blot analysis, in the presence of YKS and following the treatment with TrkA inhibitor, K252a. YKS treatment (NGF+YKS 0.5 group) enhanced NGF-induced neurite outgrowth and phosphorylation/activation of Akt and ERK1/2 in PC12 cells. Moreover, YKS-induced effects were inhibited by the treatment with the TrkA receptor antagonist K252a (NGF+YKS 0.5+K252a group); no significant difference in neurite outgrowth was observed between K252a-treated (NGF+YKS 0.5+K252a group) and NGF-K252a-treated cells (NGF+K252a group). However, neurite outgrowth in K252a-treated cells (NGF+K252a and NGF+YKS 0.5+K252a group) reached only one-third of the level in NGF-treated cells (NGF group). NGF-mediated Akt phosphorylation increased by YKS was also inhibited by K252a treatment (NGF+YKS 0.5+K252a group), but no significant difference in ERK1/2 phosphorylation was observed between NGF-YKS-K252a- and NGF-treated cells (NGF group). Our results indicate that YKS treatment enhanced NGF-induced neurite outgrowth via induction of Akt and ERK1/2 phosphorylation, following the binding of NGF to the TrkA receptor. These findings may be useful in the development of novel therapeutic strategies for the treatment of Alzheimer's disease.
|
| Volume |
18(3)
|
| Pages |
224-233
|
| Published |
2018-8-1
|
| DOI |
10.17305/bjbms.2017.2248
|
| PMID |
28961087
|
| PMC |
PMC6087561
|
| MeSH |
Alzheimer Disease / therapy
Animals
Cell Differentiation
Cell Survival
Dose-Response Relationship, Drug
Drugs, Chinese Herbal / chemistry
Drugs, Chinese Herbal / pharmacology*
Medicine, Kampo
Mice
Nerve Growth Factor / metabolism*
Neurites / metabolism*
Neuronal Outgrowth / drug effects*
PC12 Cells
Phosphorylation
Rats
Receptor, trkA / antagonists & inhibitors
Receptor, trkA / metabolism
Signal Transduction
|
| IF |
1.432
|
| Times Cited |
3
|
| Resource |
| Human and Animal Cells |
PC-12(RCB0009) |
